Pleiotropic effects of HDL: towards new therapeutic areas for HDL-targeted interventions.
Plasma levels of high density lipoprotein (HDL) cholesterol levels and of apolipoprotein A-I are inversely correlated with the incidence of coronary heart disease. According to the HDL hypothesis, raising HDL cholesterol is expected to lead to a decrease of coronary heart disease risk. The stringent requirement for proving or refuting this hypothesis is that the causal pathway between the therapeutic intervention and a hard clinical end-point obligatory passes through HDL. The lack of positive clinical results in several recent HDL trials should be interpreted in light of the poor HDL specificity of the drugs that were investigated in these trials. Nevertheless, the results of Mendelian randomization studies further raise the possibility that the epidemiological relationship between HDL cholesterol and coronary artery disease might reflect residual confounding. HDL are circulating multimolecular platforms that exert divergent functions: reverse cholesterol transport, antiinflammatory effects, anti-oxidative effects, immunomodulatory effects, improved endothelial function, increased endothelial progenitor cell number and function, antithrombotic effects, and potentiation of insulin secretion and improvement of insulin sensitivity. Pleiotropic effects of HDL might be translated in clinically significant effects in strategically selected therapeutic areas that are not directly related to native coronary artery disease. In this review, four new therapeutic areas for HDL-targeted diseases are presented: critical illness, allograft vasculopathy and vein graft atherosclerosis, type 2 diabetes mellitus, and heart failure. The strategic selection of these therapeutic areas is not only based on specific functional properties of HDL but also on significant pre-clinical and clinical data that support this choice.
S C
SC
Gordts
N
N
Singh
I
I
Muthuramu
Centre for Molecular and Vascular Biology, Department of Cardiovascular Medicine, Catholic University of Leuven, Campus Gasthuisberg, Herestraat 49, 3000 Leuven, Belgium. bart.degeest@med.kuleuven.be.
B
B
De Geest
D000818:Animals; D002318:Cardiovascular Diseases / Q000209:etiology / Q000628:therapy; D008076:Cholesterol, HDL / Q000378:metabolism; D006801:Humans; D008075:Lipoproteins, HDL / Q000737:chemistry / Q000502:physiology*; D058990:Molecular Targeted Therapy
D008076:Cholesterol, HDL; D008075:Lipoproteins, HDL